Acumen Pharmaceuticals, Inc. 8-K

What Happened

• Acumen Pharmaceuticals, Inc. announced financial results and business highlights for the year ended December 31, 2025 in a press release dated March 26, 2026 (furnished as Exhibit 99.1 to the Form 8-K).
• On the same date the company posted an updated corporate presentation (Exhibit 99.2) to its investor relations site that reflects the company’s cash, cash equivalents and marketable securities balance as of December 31, 2025 and includes disclosure of a private placement completed March 16, 2026. The Form 8-K was signed by Matthew Zuga, CFO and Chief Business Officer.

Key Details

• Filing date: March 26, 2026 (Form 8-K).
• Reporting period: Year ended December 31, 2025 (financial results and business highlights reported).
• Private placement: Completed March 16, 2026 (included in updated presentation).
• Exhibits filed: 99.1 (Earnings Press Release) and 99.2 (Corporate Presentation).

Why It Matters

• Investors get the company’s latest full‑year financial results and management highlights for 2025 — the press release (Exhibit 99.1) contains the detailed numbers and business context.
• The updated presentation discloses the company’s cash and marketable securities position as of year‑end and confirms a March 16 private placement, both important for assessing liquidity and recent financing activity.
• Review the attached press release and presentation for the specific financial figures, cash balance, and terms of the private placement to understand potential impacts on valuation or dilution.